DTE
59
3
GIS
60
-3
TROW
51
-3
ABT
48
-2
EW
42
2
GPC
61
-3
UNH
55
3
PDCO
60
2
BA
36
-2
PFG
49
3
COF
62
2
SWN
70
4
GILD
32
2
MET
53
2
TDC
62
2
AEE
43
2
DVN
44
-3
AAL
33
-3
CTSH
42
-2
ZION
55
2
DTE
59
3
GIS
60
-3
TROW
51
-3
ABT
48
-2
EW
42
2
GPC
61
-3
UNH
55
3
PDCO
60
2
BA
36
-2
PFG
49
3
COF
62
2
SWN
70
4
GILD
32
2
MET
53
2
TDC
62
2
AEE
43
2
DVN
44
-3
AAL
33
-3
CTSH
42
-2
ZION
55
2
Financhill
Back

Kiniksa Pharmaceuticals 10K Form

Buy
54

KNSA
Kiniksa Pharmaceuticals

Last Price:
17.62
Seasonality Move:
4.99%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive KNSA News And Ratings

See the #1 stock for the next 7 days that we like better than KNSA

KNSA Financial Statistics

Sales & Book Value

Annual Sales: $270.26M
Cash Flow: $4.27M
Price / Cash Flow: 98.11
Annual Sales: $6.23
Price / Book: 2.87

Profitability

EPS (TTM): 0.18000
Net Income (TTM): $14.08M
Gross Margin: $236.85M
Return on Equity: 3.45%
Return on Assets: 2.94%

Kiniksa Pharmaceuticals Earnings Forecast

Key Kiniksa Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 5 years for KNSA is 87.64%.
  • The Selling, General & Administrative Expenses for KNSA have been equal to 47.89% of Gross Profit Margin.
  • The Research & Development expenses have been 28.16% of Revenue.
  • The Net Earning history of KNSA is 5.21% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 4 years.

Kiniksa Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: KNSA
CUSIP: G5269C
Website: kiniksa.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.34
Quick Ratio: 3.58

Price-to-Earnings

Trailing P/E Ratio: 89.3
Forward P/E Ratio: 0

KNSA Technical Analysis vs Fundamental Analysis

Buy
54
Kiniksa Pharmaceuticals (KNSA) is a Buy

Is Kiniksa Pharmaceuticals a Buy or a Sell?